OTX 2002
Alternative Names: MYC-OECs; OTX-2002Latest Information Update: 15 Apr 2024
At a glance
- Originator Omega Therapeutics
- Class Antineoplastics; RNA
- Mechanism of Action Proto-oncogene protein c-myc expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Liver cancer; Solid tumours
- Preclinical Non-small cell lung cancer
- Research Small cell lung cancer
Most Recent Events
- 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Liver cancer released by Omega Therapeutics
- 28 Mar 2024 Efficacy data from a phase I/II trial in Solid tumours released by Omega Therapeutics
- 31 Dec 2023 Omega Therapeutics has patents pending for OTX 2002 in USA, Australia, Brazil, Canada, China, Eurasia, Europe, India, Japan, Mexico, New Zealand, Singapore, South Africa, Taiwan and a PCT application